These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2794289)

  • 1. Safety of allergen immunotherapy.
    Norman PS
    J Allergy Clin Immunol; 1989 Oct; 84(4 Pt 1):438-9. PubMed ID: 2794289
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy.
    Bukantz SC; Bagg AS; Lockey RF
    Clin Allergy Immunol; 2008; 21():455-68. PubMed ID: 18828523
    [No Abstract]   [Full Text] [Related]  

  • 3. Beta-adrenergic blockers, immunotherapy, and skin testing. American Academy of Allergy and Immunology.
    Kaplan AP; Anderson JA; Valentine MD; Lockey RF; Pierson WE; Zweiman B; Kaliner MA; Lichtenstein LM; Lieberman PL; Settipane GA
    J Allergy Clin Immunol; 1989 Jul; 84(1):129-30. PubMed ID: 2569002
    [No Abstract]   [Full Text] [Related]  

  • 4. Allergen injection immunotherapy (hyposensitization) on trial.
    Kay AB
    Clin Exp Allergy; 1989 Nov; 19(6):591-6. PubMed ID: 2598099
    [No Abstract]   [Full Text] [Related]  

  • 5. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy.
    Senti G; Graf N; Haug S; Rüedi N; von Moos S; Sonderegger T; Johansen P; Kündig TM
    J Allergy Clin Immunol; 2009 Nov; 124(5):997-1002. PubMed ID: 19733905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of immunotherapy.
    Williams AP; Krishna MT; Frew AJ
    Clin Exp Allergy; 2004 Apr; 34(4):513-4. PubMed ID: 15080799
    [No Abstract]   [Full Text] [Related]  

  • 7. Allergen Immunotherapy.
    Rael E
    Prim Care; 2016 Sep; 43(3):487-94. PubMed ID: 27545737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for systemic reactions to allergen-specific subcutaneous immunotherapy.
    Iglesias-Cadarso A; Hernández-Weigand P; Reaño M; Pérez-Pimiento A; Vargas Núñez JA; de la Torre F
    J Investig Allergol Clin Immunol; 2010; 20(7):621-2. PubMed ID: 21314007
    [No Abstract]   [Full Text] [Related]  

  • 9. The management of local reactions due to allergen immunotherapy.
    Taşkapan O
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):94. PubMed ID: 14756475
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of side effects in the diagnosis and treatment of allergic diseases].
    Ruppert V
    Med Welt; 1969 Mar; 11():600-2. PubMed ID: 4389017
    [No Abstract]   [Full Text] [Related]  

  • 11. Instructions and consent forms for subcutaneous allergen immunotherapy.
    Cox L; Lockey RF
    Clin Allergy Immunol; 2008; 21():499-525. PubMed ID: 18828526
    [No Abstract]   [Full Text] [Related]  

  • 12. Future of allergen-specific immunotherapy: better understanding of the mechanisms, novel treatments, and long-term cure.
    Akdis CA
    Immunol Allergy Clin North Am; 2006 May; 26(2):xiii-xxii. PubMed ID: 16701138
    [No Abstract]   [Full Text] [Related]  

  • 13. Safe allergen immunotherapy. The correct allergen, the appropriate patient, the adequate dose.
    Schoenwetter WF
    Postgrad Med; 1996 Aug; 100(2):123-6, 131-5. PubMed ID: 8700812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allergen immunotherapy: an updated review of safety.
    James C; Bernstein DI
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):55-59. PubMed ID: 27906697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy.
    Bukantz SC; Lockey RF
    Clin Allergy Immunol; 2004; 18():711-27. PubMed ID: 15042944
    [No Abstract]   [Full Text] [Related]  

  • 16. Current status of allergen immunotherapy (hyposensitization). Report of a WHO/IUIS working Group.
    Allerg Immunol (Leipz); 1989; 35(4):235-47. PubMed ID: 2696375
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal dosing of allergen immunotherapy: efficacy, safety, long-lasting effect.
    Senna G; Crivellaro MA; Bonadonna P; Dama AR; Schiappoli M; Passalaqua
    Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):386-92. PubMed ID: 14768524
    [No Abstract]   [Full Text] [Related]  

  • 18. Consensus on allergen specific immunotherapy.
    Musarra A; Bilò MB; Bonini S; Canonica GW; Senna GE
    Eur Ann Allergy Clin Immunol; 2013; 45 Suppl 3():1-49. PubMed ID: 26046171
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel routes for allergen immunotherapy: safety, efficacy and mode of action.
    Moingeon P; Mascarell L
    Immunotherapy; 2012 Feb; 4(2):201-12. PubMed ID: 22339462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allergy immunotherapy for primary care physicians.
    Stokes JR; Casale TB
    Am J Med; 2006 Oct; 119(10):820-3. PubMed ID: 17000208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.